<?xml version="1.0" encoding="UTF-8"?>
<p>Recent economic globalization and market growth has drawn attention to the role of intellectual property in international trade. As major exporters of these products, developed countries advocate the protection of intellectual property while developing countries worry that intellectual property rights only support the monopoly led by international companies and raise the price of the drugs and total medical costs, ultimately having a negative impact on public health emergency response capability. In 1995, the TRIPS agreement was implemented in Uruguay Round to join the protection of intellectual property rights and the cross-retaliation system of the General Agreement of Tariffs and Trade (GATT). Developing countries agreed to protect intellectual property in exchange for market access and trade preferences from developed countries. In particular, the U.S. used its economic hegemony, along with the trade preference “Carrot” and the big-stick policy of “Super 301 sanctions of penalty article” to force other countries to accept the TRIPS agreement [
 <xref ref-type="bibr" rid="CR4">4</xref>], causing conflict over the protection of intellectual property and the right to obtain essential medicines.
</p>
